In Paxil Fraud Scheme, Glaxo Pays The Price

Law360, New York (March 29, 2006, 12:00 AM EST) -- GlaxoSmithKline PLC will fork over $14 million to U.S. states in order to settle allegations that the drug giant forced government health plans to pay inflated prices for its widely-used antidepressant Paxil in a fraudulent scheme to block generic versions of the drug from being made.

The suit and the settlement, filed yesterday in a Pennsylvania federal court, stemmed from charges that a series of baseless patent-infringement lawsuits brought by Glaxo against generic drug-makers was part of the company’s scheme to delay the introduction of cheaper...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.